Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Food: A Three-Arm Study Examining Food Insecurity Interventions

Phase 2

Recruiting

Conditions: Cancer Patients

Interventions: Behavioral: surveys
Behavioral: Focus groups

First Posted Date: 2012-05-22

Last Posted Date: 2024-05-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 668

Registration Number: NCT01603316

Locations: 🇺🇸
Brooklyn Hospital Center, Brooklyn, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Queens Hospital Center, Jamaica, New York, United States

and more 7 locations

Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors

Completed

Conditions: Pancreatic Neuroendocrine Cancer

Interventions: Other: MRI

First Posted Date: 2012-05-21

Last Posted Date: 2019-06-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 25

Registration Number: NCT01603004

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Not Applicable

Terminated

Conditions: Acute Leukemia
Chronic Leukemia
Myelodysplastic Syndrome
Non-Hodgkins Lymphoma

Interventions: Radiation: total-body irradiation (TBI)
Drug: thiotepa
Drug: fludarabine phosphate
Drug: melphalan
Biological: anti-thymocyte globulin
Procedure: allogeneic hematopoietic stem cell transplantation
Biological: peripheral blood stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2012-05-15

Last Posted Date: 2018-08-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT01598025

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection

Phase 3

Completed

Conditions: Liver Cancer

Interventions: Procedure: Standard fluid management
Device: Goal directed fluid therapy with the Edwards EV1000 system

First Posted Date: 2012-05-10

Last Posted Date: 2017-10-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 135

Registration Number: NCT01596283

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation

Phase 2

Completed

Conditions: Leukemia

Interventions: Procedure: allogeneic hematopoietic stem cell transplantation
Device: CliniMACS

First Posted Date: 2012-05-10

Last Posted Date: 2022-12-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 116

Registration Number: NCT01596257

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cancer

Interventions: Other: Neuroimaging & Neuropsychological Evaluation

First Posted Date: 2012-05-04

Last Posted Date: 2022-06-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 36

Registration Number: NCT01591772

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer

Interventions: Drug: Gemcitabine and Cisplatin (DD GC)

First Posted Date: 2012-05-01

Last Posted Date: 2019-10-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 51

Registration Number: NCT01589094

Locations: 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Memoral Sloan Kettering Cancer Center@Phelps, Sleepy Hollow, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 5 locations

Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

Not Applicable

Active, not recruiting

Conditions: Renal Cancer

Interventions: Drug: 124IcG250

First Posted Date: 2012-04-20

Last Posted Date: 2024-05-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT01582204

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer

Phase 3

Active, not recruiting

Conditions: Cancer

Interventions: Behavioral: survey, questionaire

First Posted Date: 2012-04-18

Last Posted Date: 2024-08-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 360

Registration Number: NCT01579552

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: LDE225, Etoposide and Cisplatin

First Posted Date: 2012-04-18

Last Posted Date: 2017-08-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 19

Registration Number: NCT01579929

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy